Table I.
Clinical characteristics and time-based response criteria of patients with Sézary syndrome treated with extracorporeal photopheresis leading to durable complete remission
| Parameters | Patients | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6a | 7 | 8 | |
| Sex | w | w | w | w | w | w | m | m |
| Age at diagnosis | 38 | 46 | 54 | 66 | 68 | 79 | 53 | 71 |
| Diagnostic latency (years) | 14 | 3 | – | 1 | 10 | 5 | 9 | 1 |
| TNMB at diagnosis | T4NXM0B2 | T4N0M0B2 | T4N2MXB2 | T4bNXM0B2b | T4aN1aM0B2 | T4N2M0B2 | T4NXM0B0 | T4N0M0B2 |
| ISCL-/EORTC classification | IVA1 | IVA1 | IVA1 | IVA2 | IVA1 | IVA2 | IVA1 | IVA1 |
| Number of relapses | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 |
| Follow-up (months) | 97 | 124 | 120 | 76 | 33 | 33 | 22 | 62 |
| First line | ECP | ECP | ECP | ECPb | ECPb | ECP | ECP, Methotrexateb | ECPb |
| Second line | ECP, IFN-alphab | Bexarotene, ECPb | ECP, IFN-alpha | ECP, IFN-alpha | – | Bexarotene, ECPb | – | – |
| Third line | ECP | Bexarotene | Acitretin, ECP, IFN-alpha | – | – | – | – | – |
| Fourth line | – | Bexarotene, ECP | ECP, IFNa-alphab | – | – | – | – | – |
| Fifth line | – | – | ECP | – | – | – | – | – |
| Subsequent treatments | – | Bexarotene, pegIFNa | – | Mogamulizumab | – | Mogamulizumab | – | – |
| Time to response (skin), months | 67 | 3 | – | 61 | 2 | 8 | 3 | 3 |
| Time to response (blood), months | 93 | 21 | 56 | 31 | 3 | 10 | 1 | 29 |
| Response duration, months | – | – | – | 5 | – | 9 | – | – |
| Relapse-free survival, months | – | 86 | – | 3 | – | 9 | – | – |
| Time to progression, months | – | – | – | 66 | – | 24 | – | – |
| Time to next treatmentc, months | 67 | 18 | 22 | 70 | 30 | 11 | 20 | 60 |
The time-based criteria were assessed following recommendations from Olsen et al. (1).
This patient died 33 months after both time of diagnosis and initiation of ECP.
This treatment line was the one to achieve complete remission in both skin and blood, resulting in global complete remission for the first time.
The depicted time to next treatment corresponds to the treatment line, after which complete remission in both skin and blood was assessed for the first time.
m: male; w: female; TNMB: tumour, node, metastasis, and blood for staging regarding disease involvement according to Olsen et al. (1) and Scarisbrick et al. (5); X: unknown status regarding TNMB stage; ISCL-/EORTC classification: International Society for Cutaneous Lymphomas/ European Organization for Research and Treatment of Cancer – classification regarding staging according to Olsen et al. (1); First line: First treatment line the patient received; Second line: Second treatment line the patient received; Third line: Third treatment line the patient received; Fourth line: Fourth treatment line the patient received; Fifth line: Fifth treatment line the patient received; ECP: extracorporeal photopheresis; IFN-alpha: interferon-alpha; pegIFN-a: pegylated interferon alpha-2a; –: not available, no event, or not possible to calculate due to missing data.